Poly Medicure Approves Q2 Consolidated Financial Results Following Board Review

Market snapshot: Poly Medicure Limited held its scheduled Board of Directors meeting on November 5, 2026, to review and approve its unaudited standalone and consolidated financial results for the second quarter. The source alert indicates a consolidated net profit of ₹95.10 crore compared to ₹91.83 crore in the corresponding prior-year period (as stated in the source alert; not independently verified). Investors are watching official exchange dissemination for detailed margin breakdowns.

Data Snapshot

• Poly Medicure Board scheduled the review and approval of Q2 FY27 unaudited financial results on November 5, 2026
• Standalone EBITDA margin reached 28% in Q1 FY27, exceeding internal guided operational range of 25% to 27%
• Gross profit margin stood at 71.5% in Q1 FY27, driven by product mix optimization and selective price adjustments

Key Takeaways

• Poly Medicure convened its Board of Directors on November 5, 2026, to finalize Q2 financial statements.
• The source alert reports Q2 consolidated net profit of ₹95.10 crore versus ₹91.83 crore YoY (as stated in the source alert; not independently verified).
• Operational discipline builds on a strong Q1 baseline where standalone EBITDA margin delivered 28%.

SAHI Perspective

Poly Medicure continues to leverage its competitive position in medical devices and consumables. While preliminary alert figures point to steady profit growth, institutional interest will center on whether gross margins hold above historic levels of 68% to 69% amid evolving global trade and supply conditions.

Market Implications

Steady operational delivery supports valuation multiples in the domestic medical technology space. Investors will monitor export segment commentary and domestic adoption rates for advanced device lines.

Trading Signals

Market Bias: Insufficient data

Market bias is classified as Insufficient data pending independent exchange verification of the full financial results filing.

Trigger Factors:

• Dissemination of audited/reviewed Q2 earnings table on BSE/NSE
• Management commentary on margin guidance during upcoming analyst call

Time Horizon: Near-term (0-3 months)

Industry Context

India's medical technology and device sector benefits from expanding hospital capacity, higher health insurance coverage, and domestic manufacturing initiatives. Exporters in critical care and vascular access remain sensitive to international pricing and regulatory approvals.

Key Risks to Watch

• Raw material price volatility affecting consumable manufacturing costs
• Currency fluctuations impacting export realisations across international markets

Recent Developments

Poly Medicure conducted its 31st Annual General Meeting on September 5, 2026, following approval of all ordinary and special resolutions. In August 2026, the company reported Q1 gross margins of 71.5% supported by product mix gains.

Closing Insight

Sustained revenue momentum in core medical consumables combined with disciplined margin control remains central to Poly Medicure's medium-term growth strategy.

High Performance Trading with SAHI.